Navigation Links
Valeant Pharmaceuticals Completes Sale Of Filler And Toxin Assets To Galderma
Date:7/10/2014

LAVAL, Quebec, July 10, 2014 /PRNewswire/ -- Valeant Pharmaceuticals International, Inc. (NYSE: VRX and TSX: VRX) today announced it has completed the sale to Galderma of all rights to Restylane, Perlane, Emervel, Sculptra, and Dysport owned or held by Valeant for $1.4 billion in cash, pursuant to the previously announced agreement with Nestle S.A, which recently completed its acquisition of Galderma.

"We are pleased to complete the divestiture of our products to a company that is firmly committed to the aesthetic dermatology market," said J. Michael Pearson, chairman and chief executive officer.  "Humberto Antunes, CEO of Galderma, has embraced our commercial team and I know he will continue our efforts to build strong relationships with the healthcare leaders in this industry."

About Valeant Pharmaceuticals International, Inc.

Valeant Pharmaceuticals International, Inc. (NYSE/TSX: VRX) is a multinational specialty pharmaceutical company that develops, manufactures and markets a broad range of pharmaceutical products primarily in the areas of dermatology, eye health, neurology and branded generics.  More information about Valeant Pharmaceuticals International, Inc. can be found at www.valeant.com.

Contact Information:

Laurie W. Little
949-461-6002
laurie.little@valeant.com

Logo - http://photos.prnewswire.com/prnh/20101025/LA87217LOGO


'/>"/>
SOURCE Valeant Pharmaceuticals International, Inc.
Copyright©2014 PR Newswire.
All rights reserved

Page: 1

Related medicine technology :

1. Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc.
2. Presentation Schedules, Stock Movements, Agreements, and New Appointments - Research Report on Celgene, Merck, Bristol-Myers, Valeant, and Mylan
3. Valeant Pharmaceuticals To Present At Industry Conferences
4. Valeant Pharmaceuticals Agrees to Acquire Solta Medical for $2.92 Per Share in Cash
5. Valeant Pharmaceuticals Announces Redemption Of The Remaining $465.5 Million Aggrerate Principal Amount Of Its Outstanding 6.50% Senior Notes Due 2016
6. Valeant Pharmaceuticals Announces Pricing Of Private Offering Of Senior Notes
7. Valeant Pharmaceuticals Announced Redemption Of $450 Million Aggregate Principal Amount Of Its Outstanding 6.50% Senior Notes Due 2016
8. Valeant Pharmaceuticals Reports 2013 Third Quarter Financial Results
9. Valeant Pharmaceuticals Announces Settlement Agreement With Anacor
10. Valeant Pharmaceuticals Announces Partnership With National Coalition Against Domestic Violence
11. Valeant Pharmaceuticals Announces Continuance
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/5/2016)... , May 6, 2016 ... of liver disorders along with rise in obesity ... drugs in the coming few years. The NASH ... last five years on account of rising number ... is a large, un-tapped market with no FDA ...
(Date:5/5/2016)... -- Replikins Ltd. today reported initial promising results in animal trials of its Zika vaccine ... ... ... ... on Pubmed. The analysis identified the highest gene Replikin Counts in Zika history back ...
(Date:5/5/2016)...  Endo International plc (NASDAQ: ENDP ... Lortie , President, U.S. Branded Pharmaceuticals, has decided ... appointment of a successor. Mr. Lortie joined Endo ... with responsibility for all strategic, commercial and operational ... development, commercial operations, managed markets, manufacturing, supply chain ...
Breaking Medicine Technology:
(Date:5/6/2016)... ... 06, 2016 , ... Yisrayl Hawkins, Pastor and Overseer at The House of Yahweh, has written ... found in the Bible about helping to stop cancer. Yisrayl says there are too many ... that the health and science industries will pay close attention and take action. The Pastor ...
(Date:5/6/2016)... ... May 06, 2016 , ... Kenneth Cochran, DSc, RN, FACHE, ... of the South announced today that Dr. Robert Menuet, Interventional Cardiologist with Cardiovascular ... Ultrasound Guided Coronary Atherectomy. , This procedure involves the removal of ...
(Date:5/5/2016)... ... 2016 , ... While the practice and profession of Aging Life Care is ... has on communities and resources. Aging Life Care plays an important role as these ... , Aging Life Care is a holistic, client-centered approach to caring for older adults ...
(Date:5/5/2016)... ... 2016 , ... The U.S. Food and Drug Administration today ... submit their products through an arduous federal approval process. The rules, which treat ... market since February 15, 2007. That would essentially ban 99 percent of all ...
(Date:5/5/2016)... CA (PRWEB) , ... May 05, 2016 , ... This weekend, from Friday, May 6 ... take on steep California terrain at the first Team Semper Fi Mountain Bike Camp, hosted ... them will be mountain bike legends Mark Weir and Jason Moeschler, who’ll share pro tips ...
Breaking Medicine News(10 mins):